Cyclo Therapeutics, Inc.
CYTH
Price:
$0.68
Market Cap:
$19.51M
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2000-05-03
Stock Exchange
NASDAQ
Ticker
CYTH
The ROE as of September 2024 (TTM) for Cyclo Therapeutics, Inc. (CYTH) is 10.26%
According to Cyclo Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 10.26%. This represents a change of -15853.16% compared to the average of -65.14% of the last 4 quarters.
Cyclo Therapeutics, Inc. (CYTH) Historical ROE (quarterly & annually)
How has CYTH ROE performed in the past?
The mean historical ROE of Cyclo Therapeutics, Inc. over the last ten years is -462.02%. The current 10.26% ROE has changed -2321.00% with respect to the historical average. Over the past ten years (40 quarters), CYTH's ROE was at its highest in in the March 2022 quarter at 1.25%. The ROE was at its lowest in in the March 2024 quarter at -711.96%.
Average
-462.02%
Median
-305.69%
Minimum
-2080.19%
Maximum
-13.56%
Cyclo Therapeutics, Inc. (CYTH) ROE by Quarter and Year
Discovering the peaks and valleys of Cyclo Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.18%
Maximum Annual ROE = -13.56%
Minimum Annual Increase = -218.82%
Minimum Annual ROE = -2080.19%
| Year | ROE | Change |
|---|---|---|
| 2023 | -421.64% | -79.73% |
| 2022 | -2080.19% | 2.18% |
| 2021 | -91.28% | 6.92% |
| 2020 | -85.37% | -89.59% |
| 2019 | -819.92% | 91.25% |
| 2018 | -428.71% | 28.13% |
| 2017 | -334.58% | 20.88% |
| 2016 | -276.79% | 306.36% |
| 2015 | -68.11% | 402.22% |
| 2014 | -13.56% | -218.82% |
Cyclo Therapeutics, Inc. (CYTH) Average ROE
How has CYTH ROE performed in the past?
The current ROE of Cyclo Therapeutics, Inc. (CYTH) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-864.37%
5-year avg
-699.68%
10-year avg
-462.02%
Cyclo Therapeutics, Inc. (CYTH) ROE vs. Peers
How is CYTH’s ROE compared to its peers?
Cyclo Therapeutics, Inc.’s ROE is greater than Athenex, Inc. (-527.67%), greater than MedMen Enterprises Inc. (-34.45%), greater than Lifecore Biomedical, Inc. (26.37%), greater than Lucy Scientific Discovery Inc. (-377.80%), greater than Guardion Health Sciences, Inc. (-71.26%), less than Agile Therapeutics, Inc. (104.04%), greater than Alpha Teknova, Inc. (-38.94%), greater than Petros Pharmaceuticals, Inc. (-134.64%), greater than Phibro Animal Health Corporation (0.91%), less than SOHM, Inc. (105.08%), greater than Silver Spike Investment Corp. (5.74%), greater than Eagle Pharmaceuticals, Inc. (4.41%), greater than Intra-Cellular Therapies, Inc. (-11.48%), greater than Ironwood Pharmaceuticals, Inc. (-2.78%), greater than Amneal Pharmaceuticals, Inc. (-1322.15%), greater than Aquestive Therapeutics, Inc. (36.59%), greater than Assertio Holdings, Inc. (-231.03%), greater than AcelRx Pharmaceuticals, Inc. (-48.62%),
| Company | ROE | Market cap |
|---|---|---|
| -527.67% | $2.33M | |
| -34.45% | $138.32K | |
| 26.37% | $158.51M | |
| -377.80% | $906.91K | |
| -71.26% | $12.83M | |
| 104.04% | $10.43M | |
| -38.94% | $234.00M | |
| -134.64% | $3.64M | |
| 0.91% | $858.88M | |
| 105.08% | $2.05M | |
| 5.74% | $71.66M | |
| 4.41% | $55.71M | |
| -11.48% | $7.98B | |
| -2.78% | $721.22M | |
| -1322.15% | $2.71B | |
| 36.59% | $450.75M | |
| -231.03% | $116.31M | |
| -48.62% | $14.58M |
Build a custom stock screener for Cyclo Therapeutics, Inc. (CYTH) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cyclo Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Cyclo Therapeutics, Inc. (CYTH) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Cyclo Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Cyclo Therapeutics, Inc.'s ROE?
How is the ROE calculated for Cyclo Therapeutics, Inc. (CYTH)?
What is the highest ROE for Cyclo Therapeutics, Inc. (CYTH)?
What is the 3-year average ROE for Cyclo Therapeutics, Inc. (CYTH)?
What is the 5-year average ROE for Cyclo Therapeutics, Inc. (CYTH)?
How does the current ROE for Cyclo Therapeutics, Inc. (CYTH) compare to its historical average?